<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396342</url>
  </required_header>
  <id_info>
    <org_study_id>CT-AMT-060-01</org_study_id>
    <nct_id>NCT02396342</nct_id>
  </id_info>
  <brief_title>Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B</brief_title>
  <official_title>A Phase I/II, Open-label, Uncontrolled, Single-dose, Dose-ascending, Multi-centre Trial Investigating an Adeno-associated Viral Vector Containing a Codon-optimized Human Factor IX Gene (AAV5-hFIX) Administered to Adult Patients With Severe or Moderately Severe Hemophilia B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UniQure Biopharma B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UniQure Biopharma B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates how safe gene therapy treatment with AAV5-hFIX is in adult patients with&#xD;
      severe or moderately severe hemophilia B and severe bleeding type.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2015</start_date>
  <completion_date type="Actual">April 15, 2021</completion_date>
  <primary_completion_date type="Actual">April 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Five years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FIX-replacement-therapy-free FIX activity</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding rate</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total consumption of FIX replacement therapy</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 Quality of Life scores</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vector DNA in semen, blood, saliva, nasal secretions, urine and faeces</measure>
    <time_frame>Up to five years but maximally until the date that 3 consecutive samples are negative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibodies to AAV5</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total (IgM and IgG) antibodies to AAV5</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AAV5 capsid-specific T cells</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibodies to FIX</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FIX inhibitors</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers: Interleukin(IL)-1β, IL-2, IL-6, Interferon γ, Monocyte Chemotactic Protein-1</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AAV5-hFIX 5 × 10E12 gc/kg intravenous single infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AAV5-hFIX 2 × 10E13 gc/kg intravenous single infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>AAV5-hFIX</intervention_name>
    <description>AAV5hFIX gene therapy</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>AAV5 containing a codon-optimized human factor IX gene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Patients with congenital hemophilia B classified as one of the following:&#xD;
&#xD;
               -  Known severe FIX deficiency with plasma FIX activity level &lt; 1% and a severe&#xD;
                  bleeding phenotype defined by one of the following:&#xD;
&#xD;
                    -  Currently on prophylactic FIX replacement therapy for a history of bleeding&#xD;
&#xD;
                    -  Currently on on-demand therapy with a current or past history of frequent&#xD;
                       bleeding defined as four or more bleeding episodes in the last 12 months or&#xD;
                       chronic hemophilic arthropathy (pain, joint destruction, and loss of range&#xD;
                       of motion) in one or more joints&#xD;
&#xD;
               -  Known moderately severe FIX deficiency with plasma FIX activity level between ≥&#xD;
                  1% and ≤ 2% and a severe bleeding phenotype defined by one of the following:&#xD;
&#xD;
                    -  Currently on prophylactic FIX replacement therapy for a history of bleeding&#xD;
&#xD;
                    -  Currently on on-demand therapy with a current or past history of frequent&#xD;
                       bleeding defined as four or more bleeding episodes in the last 12 months or&#xD;
                       chronic hemophilic arthropathy (pain, joint destruction, and loss of range&#xD;
                       of motion) in one or more joints&#xD;
&#xD;
          4. More than 150 previous exposure days of treatment with FIX protein.&#xD;
&#xD;
          5. Acceptance to use a condom during sexual intercourse in the period from&#xD;
             Investigational Medicinal Product (IMP) administration until AAV5 has been cleared&#xD;
             from semen, as evidenced by the central laboratory from negative analysis results for&#xD;
             at least 3 consecutively collected semen samples (this criterion is applicable also&#xD;
             for subjects who are surgically sterilized)&#xD;
&#xD;
          6. Following receipt of verbal and written information about the trial, the subject has&#xD;
             provided signed informed consent before any trial related activity is carried out.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of FIX inhibitors measured to be ≥ 0.6 Bethesda Units (BU)/mL&#xD;
&#xD;
          2. FIX inhibitors ≥ 0.6 BU/mL at Visit 1 (measured by the local laboratory)&#xD;
&#xD;
          3. Neutralizing antibodies against AAV5 at Visit 1 (measured by the central laboratory)&#xD;
&#xD;
          4. Visit 1 laboratory values (measured by the central laboratory):&#xD;
&#xD;
               -  alanine aminotransferase &gt; 2 times upper normal limit&#xD;
&#xD;
               -  aspartate aminotransferase &gt; 2 times upper normal limit&#xD;
&#xD;
               -  total bilirubin &gt; 2 times upper normal limit&#xD;
&#xD;
               -  alkaline phosphatase &gt; 2 times upper normal limit&#xD;
&#xD;
               -  creatinine &gt; 1.5 times upper normal limit&#xD;
&#xD;
          5. Positive HIV serological test at Visit 1, not controlled with anti-viral therapy as&#xD;
             shown by cluster of differentiation 4+ counts ≤ 200 per μL or by a viral load of &gt;200&#xD;
             copies per mL (measured by the central laboratory)&#xD;
&#xD;
          6. Active infection with Hepatitis B or C virus as reflected by Hepatitis B Surface&#xD;
             Antigen (HBsAg), Hepatitis B extracellular Antigen (HBeAg), Hepatitis B Virus&#xD;
             DeoxyriboNucleic Acid (HBV DNA) or Hepatitis C Virus RiboNucleic Acid (HCV RNA)&#xD;
             positivity, respectively, at Visit 1 (measured by the central laboratory).&#xD;
&#xD;
          7. History of Hepatitis B or C exposure, currently controlled by antiviral therapy&#xD;
&#xD;
          8. Any coagulation disorder other than hemophilia B&#xD;
&#xD;
          9. Thrombocytopenia, defined as a platelet count below 50 × 10E9 / L, at Visit 1&#xD;
             (measured by the central laboratory)&#xD;
&#xD;
         10. Body mass index &lt; 16 or ≥ 35 kg/m2&#xD;
&#xD;
         11. Planned surgery for the initial 6 months after IMP administration in this trial&#xD;
&#xD;
         12. Previous arterial or venous thrombotic event (e.g. acute myocardial infarction,&#xD;
             cerebrovascular disease and venous thrombosis)&#xD;
&#xD;
         13. Active severe infection or any other significant concurrent, uncontrolled medical&#xD;
             condition including, but not limited to, renal, hepatic, haematological,&#xD;
             gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease,&#xD;
             alcoholism, drug dependency or any other psychological disorder evaluated by the&#xD;
             investigator to interfere with adherence to the protocol procedures or with the degree&#xD;
             of tolerance to the IMP&#xD;
&#xD;
         14. Known significant medical condition including disseminated intravascular coagulation,&#xD;
             fibrinolysis and liver fibrosis which, in the opinion of the investigator, may&#xD;
             confound, contraindicate or limit the interpretation of either safety or efficacy data&#xD;
&#xD;
         15. Known history of an allergic reaction or anaphylaxis to FIX products&#xD;
&#xD;
         16. Known uncontrolled allergic conditions or allergy/hypersensitivity to any component of&#xD;
             the IMP excipients&#xD;
&#xD;
         17. Previous gene therapy treatment and/or previous participation in a gene therapy&#xD;
             clinical trial&#xD;
&#xD;
         18. Receipt of an experimental agent within 60 days prior to Visit 1&#xD;
&#xD;
         19. Current participation or anticipated participation within one year after IMP&#xD;
             administration in this trial in any other interventional clinical trial involving&#xD;
             drugs or devices.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>uniQure Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>UniQure Biopharma B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>uniQure Investigative Site</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>uniQure Investigative Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>uniQure Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>uniQure Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>uniQure Investigative Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>uniQure Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>uniQure Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia B, gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

